PMID- 32708193
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2079-4991 (Print)
IS  - 2079-4991 (Electronic)
IS  - 2079-4991 (Linking)
VI  - 10
IP  - 7
DP  - 2020 Jul 21
TI  - Lipid-Based Drug Delivery Nanoplatforms for Colorectal Cancer Therapy.
LID - 10.3390/nano10071424 [doi]
LID - 1424
AB  - Colorectal cancer (CRC) is a prevalent disease worldwide, and patients at late 
      stages of CRC often suffer from a high mortality rate after surgery. Adjuvant 
      chemotherapeutics (ACs) have been extensively developed to improve the survival 
      rate of such patients, but conventionally formulated ACs inevitably distribute 
      toxic chemotherapeutic drugs to healthy organs and thus often trigger severe side 
      effects. CRC cells may also develop drug resistance following repeat dosing of 
      conventional ACs, limiting their effectiveness. Given these limitations, 
      researchers have sought to use targeted drug delivery systems (DDSs), 
      specifically the nanotechnology-based DDSs, to deliver the ACs. As lipid-based 
      nanoplatforms have shown the potential to improve the efficacy and safety of 
      various cytotoxic drugs (such as paclitaxel and vincristine) in the clinical 
      treatment of gastric cancer and leukemia, the preclinical progress of lipid-based 
      nanoplatforms has attracted increasing interest. The lipid-based nanoplatforms 
      might be the most promising DDSs to succeed in entering a clinical trial for CRC 
      treatment. This review will briefly examine the history of preclinical research 
      on lipid-based nanoplatforms, summarize the current progress, and discuss the 
      challenges and prospects of using such approaches in the treatment of CRC.
FAU - Yang, Chunhua
AU  - Yang C
AUID- ORCID: 0000-0003-0805-1008
AD  - Institute for Biomedical Sciences, Center for Diagnostics and Therapeutics, 
      Digestive Disease Research Group, Georgia State University, Atlanta, GA 30302, 
      USA.
FAU - Merlin, Didier
AU  - Merlin D
AD  - Institute for Biomedical Sciences, Center for Diagnostics and Therapeutics, 
      Digestive Disease Research Group, Georgia State University, Atlanta, GA 30302, 
      USA.
AD  - Atlanta Veterans Affairs Medical Center, Decatur, GA 30033, USA.
LA  - eng
GR  - RO1-DK-116306/DK/NIDDK NIH HHS/United States
GR  - RO1-DK-107739/DK/NIDDK NIH HHS/United States
GR  - BX002526/U.S. Department of Veterans Affairs/
GR  - BX004476/U.S. Department of Veterans Affairs/
PT  - Journal Article
PT  - Review
DEP - 20200721
PL  - Switzerland
TA  - Nanomaterials (Basel)
JT  - Nanomaterials (Basel, Switzerland)
JID - 101610216
PMC - PMC7408503
OTO - NOTNLM
OT  - colorectal cancer
OT  - exosomes
OT  - lipid-based nanoparticles
OT  - plant-derived lipid nanoparticles
OT  - targeted drug delivery
COIS- We declare no potential conflicts of interest in this review.
EDAT- 2020/07/28 06:00
MHDA- 2020/07/28 06:01
PMCR- 2020/07/21
CRDT- 2020/07/26 06:00
PHST- 2020/07/02 00:00 [received]
PHST- 2020/07/15 00:00 [revised]
PHST- 2020/07/20 00:00 [accepted]
PHST- 2020/07/26 06:00 [entrez]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2020/07/28 06:01 [medline]
PHST- 2020/07/21 00:00 [pmc-release]
AID - nano10071424 [pii]
AID - nanomaterials-10-01424 [pii]
AID - 10.3390/nano10071424 [doi]
PST - epublish
SO  - Nanomaterials (Basel). 2020 Jul 21;10(7):1424. doi: 10.3390/nano10071424.